Cargando…
Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion
Ovarian cancer (OC) has a poor prognosis as most patients present with non-specific symptoms and the disease is mostly diagnosed at advanced stages. Approximately 90% of cases are classified as epithelial OC (EOC), a category comprising histologically and molecularly distinct tumours. Identifying re...
Autores principales: | Vergote, I, Denys, H, Altintas, S, Kerger, J, Baurain, J-F, Bours, V, Henry, S, Van de Vijver, K, Lambrechts, D, Gennigens, C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Universa Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191713/ https://www.ncbi.nlm.nih.gov/pubmed/35781107 http://dx.doi.org/10.52054/FVVO.14.2.024 |
Ejemplares similares
-
Treatment algorithm in patients with ovarian cancer
por: Vergote, I, et al.
Publicado: (2020) -
Experts Opinion
por: Goldberg, Ivan, et al.
Publicado: (2012) -
Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
por: Akinjiyan, Favour A., et al.
Publicado: (2023) -
Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion
por: Leblanc, Dominique, et al.
Publicado: (2023) -
The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)